[ 18F]desmethoxyfallypride as a novel PET radiotracer for quantitative in vivo dopamine D2/D3 receptor imaging in rat models of neurodegenerative diseases

Nuclear Medicine and Biology

Volumn 39, Issue 7, 2012, Pages 1077-1080

  Döbrössy, Máté D ^a   Braun, Friederike ^a   Klein, Stefanie ^b   Garcia, Joanna ^a   Langen, Karl Josef ^b   Weber, Wolfgang A ^a   Nikkhah, Guido ^a   Meyer, Philipp T ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

18F desmethoxyfallypride; Animal model; Huntington's disease; Neurodegeneration; Parkinson's disease; Positron emission tomography

Indexed keywords

DESMETHOXYFALLYPRIDE F 18; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; RACLOPRIDE H 3; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG; DESMETHOXYFALLYPRIDE; DIAGNOSTIC AGENT; RACLOPRIDE; SALICYLAMIDE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG UPTAKE; FEMALE; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR IMAGING; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RADIOACTIVITY; RAT; RECEPTOR BINDING; ANIMAL; DISEASE MODEL; METABOLISM; METHODOLOGY; SCINTISCANNING;

ANIMALS; DISEASE MODELS, ANIMAL; HUNTINGTON DISEASE; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RADIOACTIVE TRACERS; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SALICYLAMIDES;

EID: 84866012746     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.04.003     Document Type: Article

References (20)

1. Phillips W., Michell A., Pruess H., Barker R.A. Animal models of neurodegenerative diseases. Methods Mol Biol 2009, 549:137-155.
2. Dunnett S.B., Rosser A.E. Clinical translation of cell transplantation in the brain. Curr Opin Organ Transplant 2011, 16:632-639.
3. Wijeyekoon R., Barker R.A. The current status of neural grafting in the treatment of Huntington's disease. A review. Front Integr Neurosci 2011, 5:1-14.
4. Döbrössy M., Büchele F., Nikkhah G. Excitotoxic lesions of the rodent striatum. Animal models of movement disorders: volume II 2011, 21-36. Springer, London. E.L. Lane, S.B. Dunnett (Eds.).
5. Simola N., Morelli M., Carta A.R. The 6-hydroxydopamine model of Parkinson's disease. Neurotox Res 2007, 11:151-167.
6. Strome E.M., Doudet D.J. Animal models of neurodegenerative disease: insights from in vivo imaging studies. Mol Imaging Biol 2007, 9:186-195.
7. Hume S.P., Gunn R.N., Jones T. Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals. Eur J Nucl Med 1998, 25:173-176.
8. Mukherjee J., Yang Z.Y., Brown T., Roemer J., Cooper M. 18F-desmethoxyfallypride: a fluorine-18 labeled radiotracer with properties similar to carbon-11 raclopride for PET imaging studies of dopamine D2 receptors. Life Sci 1996, 59:669-678.
9. Rominger A., Wagner E., Mille E., Böning G., Esmaeilzadeh M., Wängler B., et al. Endogenous competition against binding of [(18)F]DMFP and [(18)F]fallypride to dopamine D(2/3) receptors in brain of living mouse. Synapse 2010, 64:313-322.
10. Constantinescu C.C., Coleman R.A., Pan M.L., Mukherjee J. Striatal and extrastriatal microPET imaging of D2/D3 dopamine receptors in rat brain with [18F]fallypride and [18F]desmethoxyfallypride. Synapse 2011, 65:778-787.
11. Jiang W., Büchele F., Papazoglou A., Döbrössy M., Nikkhah G. Multi-tract microtransplantation increases the yield of DARPP-32 positive embryonic striatal cells in a rodent model of Huntington's disease. Cell Transplant 2011, 20:1515-1527.
12. García J., Carlsson T., Döbrössy M., Nikkhah G., Winkler C. Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia. Neurobiol Dis 2011, 43:576-587.
13. Paxinos G., Watson C. The Rat brain in stereotaxic coordinates 1998, Academic Press, Spiral Bound, New York. 4th ed.
14. Logan L., Fowler J.S., Volkow N.D., Wang G.J., Ding Y.S., Alexoff D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996, 16:834-840.
15. Meyer P.T., Salber D., Schiefer J., Cremer M., Schaefer W.M., Kosinski C.M., et al. Comparison of intravenous and intraperitoneal [123I]IBZM injection for dopamine D2 receptor imaging in mice. Nucl Med Biol 2008, 35:543-548.
16. Topping G.J., Dinelle K., Kornelsen R., McCormick S., Holden J.E., Sossi V. Positron emission tomography kinetic modelling algorithms for small animal dopaminergic system imaging. Synapse 2010, 64:200-208.
17. Sossi V., Dinelle K., Topping G.J., Holden J.E., Doudet D., Schulzer M., et al. Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study. J Neurochem 2009, 109:85-92.
18. Palner M., Kjaerby C., Knudsen G.M., Cumming P. Effects of unilateral 6-OHDA lesions on [3H]-N-propylnorapomorphine binding in striatum ex vivo and vulnerability to amphetamine-evoked dopamine release in rat. Neurochem Int 2011, 58:243-247.
19. Inaji M., Okauchi T., Ando K., Maeda J., Nagai Y., Yoshizaki T., et al. Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats. Brain Res 2005, 1064:136-145.
20. Brownell A.L., Hantraye P., Wullner U., Hamberg L., Shoup T., Elmaleh D.R., et al. PET- and MRI-based assessment of glucose utilization, dopamine receptor binding, and hemodynamic changes after lesions to the caudate-putamen in primates. Exp Neurol 1994, 125:41-51.